1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Cancer	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	major	_	_	JJ	_	_	_	_	_
5	cause	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	human	_	_	JJ	_	_	_	_	_
8	death	_	_	NN	_	_	_	_	_
9	worldwide	_	_	RB	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	cancer	_	_	NN	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	receive	_	_	VBP	_	_	_	_	_
5	chemotherapy	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	radiation	_	_	NN	_	_	_	_	_
8	therapy	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	they	_	_	PRP	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	often	_	_	RB	_	_	_	_	_
13	only	_	_	RB	_	_	_	_	_
14	partially	_	_	RB	_	_	_	_	_
15	effective	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	lead	_	_	VBP	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	variety	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	serious	_	_	JJ	_	_	_	_	_
23	side	_	_	NN	_	_	_	_	_
24	effects	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	decades	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	cancer	_	_	NN	_	_	_	_	_
6	immunotherapy	_	_	NN	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	validated	_	_	VBN	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	stimulating	_	_	VBG	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	’	_	_	POS	_	_	_	_	_
14	own	_	_	JJ	_	_	_	_	_
15	immune	_	_	JJ	_	_	_	_	_
16	systems	_	_	NNS	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	eliminate	_	_	VB	_	_	_	_	_
19	cancers	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Compared	_	_	VBN	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	chemotherapy	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	radiation	_	_	NN	_	_	_	_	_
6	therapy	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	cancer	_	_	NN	_	_	_	_	_
9	immunotherapy	_	_	NN	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	specifically	_	_	RB	_	_	_	_	_
12	target	_	_	VB	_	_	_	_	_
13	tumor	_	_	NN	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	modulating	_	_	VBG	_	_	_	_	_
17	immune	_	_	JJ	_	_	_	_	_
18	cells	_	_	NNS	_	_	_	_	_
19	without	_	_	IN	_	_	_	_	_
20	damage	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	normal	_	_	JJ	_	_	_	_	_
23	cells	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	variety	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	cancer	_	_	NN	_	_	_	_	_
5	immunotherapies	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	including	_	_	VBG	_	_	_	_	_
8	DC-based	_	_	JJ	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	vaccines	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	chimeric	_	_	JJ	_	_	_	_	_
13	antigen	_	_	NN	_	_	_	_	_
14	receptor-T	_	_	NN	_	_	_	_	_
15	lymphocyte	_	_	NN	_	_	_	_	_
16	therapies	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	immune	_	_	JJ	_	_	_	_	_
19	checkpoint	_	_	NN	_	_	_	_	_
20	blockade	_	_	NN	_	_	_	_	_
21	antibody	_	_	NN	_	_	_	_	_
22	therapies	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	oncolytic	_	_	JJ	_	_	_	_	_
25	vaccine	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	cytokines	_	_	NNS	_	_	_	_	_
29	therapies	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	have	_	_	VBP	_	_	_	_	_
32	been	_	_	VBN	_	_	_	_	_
33	developed	_	_	VBN	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	induce	_	_	VB	_	_	_	_	_
36	tumor-specific	_	_	JJ	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	cytotoxic	_	_	JJ	_	_	_	_	_
39	T	_	_	NN	_	_	_	_	_
40	lymphocyte	_	_	NN	_	_	_	_	_
41	immune	_	_	JJ	_	_	_	_	_
42	responses	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Dendritic	_	_	JJ	_	_	_	_	_
2	cell	_	_	NN	_	_	_	_	_
3	based	_	_	VBN	_	_	_	_	_
4	therapies	_	_	NNS	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	widely	_	_	RB	_	_	_	_	_
8	investigated	_	_	VBN	_	_	_	_	_
9	because	_	_	IN	_	_	_	_	_
10	dendritic	_	_	JJ	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	DCs	_	_	NNS	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	thought	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	initiator	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	modulating	_	_	VBG	_	_	_	_	_
23	immunity	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	DCs	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	known	_	_	VBN	_	_	_	_	_
4	as	_	_	IN	_	_	_	_	_
5	professional	_	_	JJ	_	_	_	_	_
6	antigen-presenting	_	_	JJ	_	_	_	_	_
7	cells	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	responsible	_	_	JJ	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	swallowing	_	_	VBG	_	_	_	_	_
12	tumor-associated	_	_	JJ	_	_	_	_	_
13	antigens	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	presenting	_	_	VBG	_	_	_	_	_
16	them	_	_	PRP	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	T	_	_	NN	_	_	_	_	_
19	lymphocytes	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	inducing	_	_	VBG	_	_	_	_	_
23	antigen-specific	_	_	JJ	_	_	_	_	_
24	immune	_	_	JJ	_	_	_	_	_
25	responses	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	DCs	_	_	NNS	_	_	_	_	_
3	mature	_	_	VBP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	become	_	_	VBP	_	_	_	_	_
6	activated	_	_	VBN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	they	_	_	PRP	_	_	_	_	_
9	will	_	_	MD	_	_	_	_	_
10	swallow	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	foreign	_	_	JJ	_	_	_	_	_
13	substances	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	subsequently	_	_	RB	_	_	_	_	_
16	present	_	_	VB	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	antigenic	_	_	JJ	_	_	_	_	_
19	epitopes	_	_	NNS	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	major	_	_	JJ	_	_	_	_	_
22	histocompatibility	_	_	NN	_	_	_	_	_
23	complex	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	MHC	_	_	NNP	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	molecules	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	At	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	same	_	_	JJ	_	_	_	_	_
4	time	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	DCs	_	_	NNPS	_	_	_	_	_
7	up-regulate	_	_	VBP	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	maturation	_	_	NN	_	_	_	_	_
10	receptor	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	release	_	_	VB	_	_	_	_	_
13	potent	_	_	JJ	_	_	_	_	_
14	cytokines	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	migrate	_	_	VB	_	_	_	_	_
18	into	_	_	IN	_	_	_	_	_
19	lymph	_	_	NN	_	_	_	_	_
20	nodes	_	_	NNS	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	induce	_	_	VB	_	_	_	_	_
23	systemic	_	_	JJ	_	_	_	_	_
24	immune	_	_	JJ	_	_	_	_	_
25	responses	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	standard	_	_	JJ	_	_	_	_	_
3	DC-based	_	_	JJ	_	_	_	_	_
4	vaccine	_	_	NN	_	_	_	_	_
5	begins	_	_	VBZ	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	first	_	_	JJ	_	_	_	_	_
8	isolating	_	_	VBG	_	_	_	_	_
9	DCs	_	_	NNS	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	patient	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Then	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	DCs	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	stimulated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	patient	_	_	NN	_	_	_	_	_
9	’s	_	_	POS	_	_	_	_	_
10	tumor-associated	_	_	JJ	_	_	_	_	_
11	antigen	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	vitro	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	antigen-stimulated	_	_	JJ	_	_	_	_	_
18	DCs	_	_	NNS	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	injected	_	_	VBN	_	_	_	_	_
21	directly	_	_	RB	_	_	_	_	_
22	back	_	_	RB	_	_	_	_	_
23	into	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	patient	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	induce	_	_	VB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	activation	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	T	_	_	NN	_	_	_	_	_
32	lymphocytes	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	patient	_	_	NN	_	_	_	_	_
3	’s	_	_	POS	_	_	_	_	_
4	immune	_	_	JJ	_	_	_	_	_
5	system	_	_	NN	_	_	_	_	_
6	will	_	_	MD	_	_	_	_	_
7	generate	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	tumor-specific	_	_	JJ	_	_	_	_	_
10	immune	_	_	JJ	_	_	_	_	_
11	response	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	destroy	_	_	VB	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	prevent	_	_	VB	_	_	_	_	_
18	cancer	_	_	NN	_	_	_	_	_
19	recurrence	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	drawbacks	_	_	NNS	_	_	_	_	_
5	restrict	_	_	VBP	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	clinical	_	_	JJ	_	_	_	_	_
8	efficacy	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	DC	_	_	NNP	_	_	_	_	_
11	therapy	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	First	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	only	_	_	RB	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	few	_	_	JJ	_	_	_	_	_
6	DCs	_	_	NNS	_	_	_	_	_
7	actually	_	_	RB	_	_	_	_	_
8	migrate	_	_	VBP	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	lymph	_	_	NN	_	_	_	_	_
12	nodes	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	interact	_	_	VB	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	T	_	_	NNP	_	_	_	_	_
17	lymphocytes	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	result	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	failure	_	_	NN	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	induce	_	_	VB	_	_	_	_	_
27	antitumor	_	_	NN	_	_	_	_	_
28	immune	_	_	JJ	_	_	_	_	_
29	responses	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	in	_	_	FW	_	_	_	_	_
5	vitro	_	_	NN	_	_	_	_	_
6	culture	_	_	NN	_	_	_	_	_
7	cannot	_	_	MD	_	_	_	_	_
8	generate	_	_	VB	_	_	_	_	_
9	sufficiently	_	_	RB	_	_	_	_	_
10	powerful	_	_	JJ	_	_	_	_	_
11	DCs	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	result	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	weak	_	_	JJ	_	_	_	_	_
19	immune	_	_	JJ	_	_	_	_	_
20	response	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	limited	_	_	JJ	_	_	_	_	_
23	therapeutic	_	_	JJ	_	_	_	_	_
24	benefit	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	important	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	establish	_	_	VB	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	in	_	_	FW	_	_	_	_	_
10	vitro	_	_	NN	_	_	_	_	_
11	culturing	_	_	NN	_	_	_	_	_
12	system	_	_	NN	_	_	_	_	_
13	or	_	_	CC	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	in	_	_	FW	_	_	_	_	_
16	vivo	_	_	NN	_	_	_	_	_
17	DC	_	_	NNP	_	_	_	_	_
18	delivery	_	_	NN	_	_	_	_	_
19	system	_	_	NN	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	more	_	_	RBR	_	_	_	_	_
23	reliably	_	_	RB	_	_	_	_	_
24	induce	_	_	VB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	immune	_	_	JJ	_	_	_	_	_
27	response	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	more	_	_	RBR	_	_	_	_	_
30	potently	_	_	RB	_	_	_	_	_
31	deliver	_	_	VB	_	_	_	_	_
32	antitumor	_	_	JJ	_	_	_	_	_
33	immunity	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	lymph	_	_	NN	_	_	_	_	_
3	nodes	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	extremely	_	_	RB	_	_	_	_	_
6	critical	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	responses	_	_	NNS	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	pathogens	_	_	NNS	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	danger	_	_	NN	_	_	_	_	_
13	signals	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	their	_	_	PRP$	_	_	_	_	_
17	major	_	_	JJ	_	_	_	_	_
18	functions	_	_	NNS	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	filter	_	_	VB	_	_	_	_	_
22	out	_	_	RP	_	_	_	_	_
23	deleterious	_	_	JJ	_	_	_	_	_
24	substances	_	_	NNS	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	their	_	_	PRP$	_	_	_	_	_
27	unique	_	_	JJ	_	_	_	_	_
28	mesh	_	_	NN	_	_	_	_	_
29	microstructure	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	maintain	_	_	VB	_	_	_	_	_
33	matured	_	_	VBN	_	_	_	_	_
34	immunocytes	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	to	_	_	TO	_	_	_	_	_
38	initiate	_	_	VB	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	antigen-specific	_	_	JJ	_	_	_	_	_
41	adaptive	_	_	JJ	_	_	_	_	_
42	immune	_	_	JJ	_	_	_	_	_
43	response	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	lymph	_	_	NN	_	_	_	_	_
3	nodes	_	_	NNS	_	_	_	_	_
4	might	_	_	MD	_	_	_	_	_
5	lose	_	_	VB	_	_	_	_	_
6	their	_	_	PRP$	_	_	_	_	_
7	function	_	_	NN	_	_	_	_	_
8	because	_	_	IN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	obstruction	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	infection	_	_	NN	_	_	_	_	_
16	;	_	_	:	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	such	_	_	JJ	_	_	_	_	_
19	cases	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	surgical	_	_	JJ	_	_	_	_	_
22	resection	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	lymph	_	_	NN	_	_	_	_	_
25	nodes	_	_	NNS	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	usually	_	_	RB	_	_	_	_	_
28	indicated	_	_	VBN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	lymph	_	_	NN	_	_	_	_	_
4	node	_	_	NN	_	_	_	_	_
5	resection	_	_	NN	_	_	_	_	_
6	often	_	_	RB	_	_	_	_	_
7	causes	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	wide	_	_	JJ	_	_	_	_	_
10	range	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	other	_	_	JJ	_	_	_	_	_
13	problems	_	_	NNS	_	_	_	_	_
14	such	_	_	JJ	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	increased	_	_	VBN	_	_	_	_	_
17	infection	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	impaired	_	_	VBN	_	_	_	_	_
20	cancer	_	_	NN	_	_	_	_	_
21	surveillance	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	lymphedema	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Consequently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	promising	_	_	JJ	_	_	_	_	_
5	technique	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	functional	_	_	JJ	_	_	_	_	_
8	lymph	_	_	NN	_	_	_	_	_
9	node	_	_	NN	_	_	_	_	_
10	restoration	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	urgently	_	_	RB	_	_	_	_	_
13	needed	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Decellularization	_	_	NN	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	emerged	_	_	VBN	_	_	_	_	_
4	as	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	process	_	_	NN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	producing	_	_	VBG	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	natural	_	_	JJ	_	_	_	_	_
11	extracellular	_	_	JJ	_	_	_	_	_
12	matrix	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	ECM	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	preserves	_	_	VBZ	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	intrinsic	_	_	JJ	_	_	_	_	_
21	biological	_	_	JJ	_	_	_	_	_
22	cues	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	architectural	_	_	JJ	_	_	_	_	_
25	structure	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	original	_	_	JJ	_	_	_	_	_
29	tissue	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	provides	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	strategy	_	_	NN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	which	_	_	WDT	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	fabricate	_	_	VB	_	_	_	_	_
9	lymph	_	_	NN	_	_	_	_	_
10	node	_	_	NN	_	_	_	_	_
11	scaffolds	_	_	NNS	_	_	_	_	_
12	on	_	_	IN	_	_	_	_	_
13	which	_	_	WDT	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	grow	_	_	VB	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	immunological	_	_	JJ	_	_	_	_	_
20	function	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	demonstrated	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	spleen-derived	_	_	JJ	_	_	_	_	_
6	decellularized	_	_	VBN	_	_	_	_	_
7	ECM	_	_	NN	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	lymph	_	_	NN	_	_	_	_	_
10	node-associated	_	_	JJ	_	_	_	_	_
11	decellularized	_	_	VBN	_	_	_	_	_
12	ECM	_	_	NN	_	_	_	_	_
13	can	_	_	MD	_	_	_	_	_
14	deliver	_	_	VB	_	_	_	_	_
15	immune	_	_	JJ	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	promote	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	organization	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	lymphoid-like	_	_	JJ	_	_	_	_	_
23	scaffolds	_	_	NNS	_	_	_	_	_
24	;	_	_	:	_	_	_	_	_
25	however	_	_	RB	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	whether	_	_	IN	_	_	_	_	_
28	these	_	_	DT	_	_	_	_	_
29	can	_	_	MD	_	_	_	_	_
30	induce	_	_	VB	_	_	_	_	_
31	antigen-specific	_	_	JJ	_	_	_	_	_
32	immunity	_	_	NN	_	_	_	_	_
33	or	_	_	CC	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	antitumor	_	_	NN	_	_	_	_	_
36	immune	_	_	JJ	_	_	_	_	_
37	response	_	_	NN	_	_	_	_	_
38	is	_	_	VBZ	_	_	_	_	_
39	still	_	_	RB	_	_	_	_	_
40	unknown	_	_	JJ	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	establish	_	_	VB	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	natural	_	_	JJ	_	_	_	_	_
11	decellularized	_	_	VBN	_	_	_	_	_
12	lymph	_	_	NN	_	_	_	_	_
13	node	_	_	NN	_	_	_	_	_
14	scaffold	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	dLN	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	preserved	_	_	VBN	_	_	_	_	_
21	original	_	_	JJ	_	_	_	_	_
22	microstructure	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	ECM	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	validate	_	_	VB	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	ability	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	dLN	_	_	NN	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	support	_	_	VB	_	_	_	_	_
36	DC	_	_	NNP	_	_	_	_	_
37	proliferation	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	maturation	_	_	NN	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	vitro	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	aimed	_	_	VBD	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	verify	_	_	VB	_	_	_	_	_
7	whether	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	bone	_	_	NN	_	_	_	_	_
10	marrow	_	_	NN	_	_	_	_	_
11	dendritic	_	_	JJ	_	_	_	_	_
12	cell	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	BMDC)-dLN	_	_	NN	_	_	_	_	_
15	can	_	_	MD	_	_	_	_	_
16	activate	_	_	VB	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	specific	_	_	JJ	_	_	_	_	_
19	antitumor	_	_	NN	_	_	_	_	_
20	immune	_	_	JJ	_	_	_	_	_
21	response	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	vivo	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_

